United States · Wires & real time · PR Newswire

Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients Who Are Not…

Published by PR Newswire · United States 2 h ago

MUMBAI, India and PRINCETON, N.J., Oct. 20, 2026 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together…

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading

Business Wire

MIPI Alliance Announces Board Leadership Appointments

Associated Press (Business)

Houthi strikes on Saudi Arabia show the Yemeni rebels’ growing strength

Dow Jones Newswires

Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients Who Are Not…

Share

Also worth reading

MIPI Alliance Announces Board Leadership Appointments

Houthi strikes on Saudi Arabia show the Yemeni rebels’ growing strength

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening